UniSuper Management Pty Ltd lessened its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 93.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 21,700 shares of the company's stock after selling 287,473 shares during the quarter. UniSuper Management Pty Ltd's holdings in Teva Pharmaceutical Industries were worth $478,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of TEVA. Stifel Financial Corp boosted its position in Teva Pharmaceutical Industries by 54.0% during the third quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock valued at $1,196,000 after acquiring an additional 23,283 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock valued at $10,983,000 after purchasing an additional 33,277 shares in the last quarter. Pinnbrook Capital Management LP purchased a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $4,966,000. Asset Management One Co. Ltd. boosted its holdings in Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after acquiring an additional 58,413 shares during the last quarter. Finally, CWA Asset Management Group LLC bought a new stake in Teva Pharmaceutical Industries in the 4th quarter worth about $3,340,000. 54.05% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the company. StockNews.com cut Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Thursday, March 27th. Bank of America cut their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Piper Sandler increased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Finally, Barclays decreased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $23.43.
Check Out Our Latest Research Report on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Price Performance
Shares of NYSE:TEVA traded up $0.02 during trading on Wednesday, reaching $15.31. The company had a trading volume of 7,736,317 shares, compared to its average volume of 9,703,865. The company has a fifty day moving average of $16.95 and a two-hundred day moving average of $18.08. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The stock has a market capitalization of $17.36 billion, a P/E ratio of -10.56, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.
Teva Pharmaceutical Industries Profile
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Further Reading
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
